Table 2 Cox regression for overall and disease-free survival using standard prognostic variables.

From: Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents

Prognostic variable

Hazard ratio

Lower .95

Upper .95

p value

Overall survival

 Tumor type

3.0388

1.7407

5.305

9.25 × 10−5

 Nottingham grade

0.9422

0.6846

1.297

0.7148

 Pathologic tumor stage (pT)

1.1076

0.8480

1.447

0.4532

 Pathologic lymph node stage (pN)

0.8504

0.6531

1.107

0.2290

 ER

1.7590

0.9906

3.124

0.0539

 PR

0.7111

0.4264

1.186

0.1915

 HER2 IHC

0.7177

0.4879

1.056

0.0921

Disease-free survival

 Tumor type

2.6552

1.4963

4.712

0.0008

 Nottingham grade

0.8722

0.6361

1.196

0.3960

 Pathologic tumor stage (pT)

1.2423

0.9337

1.653

0.1364

 Pathologic lymph node stage (pN)

0.8707

0.6706

1.131

0.2987

 ER

1.6053

0.9130

2.823

0.1002

 PR

0.6708

0.4031

1.116

0.1244

 HER2 IHC

0.7595

0.5199

1.109

0.1547

  1. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, PR progesterone receptor.
Back to article page